LAM (lymphangioleiomyomatosis) is not hereditary in the vast majority of cases. More than 80% of LAM patients seen in pulmonary clinics have the sporadic form of the disease, which arises from random genetic mutations that occur during a person’s lifetime and cannot be passed to children. However, a smaller number of cases are linked to an inherited condition called tuberous sclerosis complex (TSC), and that form does carry a hereditary risk.
Why Most LAM Cases Are Not Inherited
LAM develops when cells in the lungs and lymphatic system grow out of control due to mutations in a gene called TSC2. In sporadic LAM, these mutations are somatic, meaning they happen spontaneously in specific cells rather than being present in every cell of the body from birth. Researchers confirmed this by comparing tissue samples: the TSC2 mutation appeared in abnormal lung cells and kidney tumors of sporadic LAM patients but was completely absent from their normal kidney tissue, healthy lung tissue, and blood cells. Because the mutation exists only in affected tissue, it is not carried in eggs or sperm and cannot be inherited by a child.
One proposed explanation is somatic mosaicism, where a mutation arises early in development and affects only certain cell lines. This pattern is common in conditions involving tumor suppressor genes, and it helps explain how the same mutation can show up in both the lungs and kidneys without being present throughout the entire body.
When LAM Is Connected to an Inherited Condition
The exception is TSC-LAM, which occurs in people who have tuberous sclerosis complex. TSC is a genetic disorder that causes benign tumors to grow in multiple organs, including the brain, kidneys, heart, and lungs. About one-third of people with TSC inherited a changed TSC1 or TSC2 gene from a parent. The remaining two-thirds developed a new mutation on their own.
If you have TSC, there is up to a 50% chance of passing the altered gene to each biological child. That child would then be at risk for all features of TSC, including the potential to develop LAM. This is the only scenario in which LAM has a truly hereditary component. Genetic counseling guidelines recommend that anyone diagnosed with TSC complete a three-generation family history to identify other relatives who may be at risk, and genetic testing is offered when the diagnosis is uncertain or when family planning decisions are involved.
How Doctors Distinguish the Two Forms
If you’re diagnosed with LAM, your medical team will look for signs of TSC, such as characteristic skin findings, kidney tumors, or brain abnormalities. LAM is classified as TSC-associated when those features are present. Otherwise, it’s considered sporadic. Both forms involve the same core problem: mutations in TSC1 or TSC2 that disable their role as tumor suppressors, leading to uncontrolled activation of a cellular growth pathway called mTOR.
A blood test measuring a protein called VEGF-D can help confirm a LAM diagnosis without a lung biopsy. A level at or above 800 pg/mL, combined with typical findings on a high-resolution CT scan, is enough for a definitive diagnosis. Lower thresholds (around 430 pg/mL) catch more cases but with less certainty.
Why LAM Almost Exclusively Affects Women
LAM occurs almost entirely in women, and estrogen plays a central role. In cells that lack a functional TSC2 gene, estrogen reactivates a signaling protein called Akt, which ramps up glucose uptake and shifts cells toward a metabolic pathway that helps them survive under stress. This effectively fuels the growth and spread of LAM cells. Research has shown that estrogen also boosts levels of a key enzyme in this metabolic pathway, and blocking either Akt or that enzyme significantly reduces the ability of TSC2-deficient cells to colonize the lungs in laboratory models. This hormonal connection is why LAM typically appears during childbearing years and can worsen during pregnancy.
What This Means for Your Family
If you have sporadic LAM, the genetic change driving your disease exists only in affected tissues. Your children do not inherit it, and there is no known increased risk of LAM in your biological relatives. Standard genetic testing of blood or saliva would not detect the mutation because it simply isn’t there in those cells.
If you have TSC-LAM, the situation is different. Because the TSC gene mutation is present in every cell, each pregnancy carries up to a 50% chance of passing TSC to a child. Not every person with TSC develops LAM, but the possibility exists, particularly for daughters. Genetic testing and counseling can help clarify your specific mutation and what it means for family planning.
Living With LAM: Outlook and Treatment
LAM is a chronic, progressive disease, but survival rates have improved considerably. The 10-year overall survival rate is approximately 91%, and even studies with longer follow-up generally report 10-year rates between 76% and 91% depending on the population. A large study of 401 patients found an 86% transplant-free survival rate at 10 years, meaning the vast majority of patients did not need a lung transplant within that window.
The clinical course varies widely. Some patients experience a slow, gradual decline in lung function over decades, while others progress more quickly. The primary treatment targets the mTOR pathway that drives LAM cell growth, slowing disease progression for many patients. Hormonal therapies, once tried based on the estrogen connection, are no longer recommended because clinical evidence did not support their effectiveness.